3415-08-5 L-Tyr-NCA

3415-08-5   L-Tyr-NCA is one of intermediates of Glatiramer Acetate.

Glatiramer Acetate is a synthetically prepared peptide agent composed of four amino acids: glutamic acid, alanine, tyrosine, and lysine. Its primary application lies in the treatment of Multiple Sclerosis (MS), a chronic, inflammatory, demyelinating disease affecting the central nervous system. Through the mechanism of "bypass suppression," Glatiramer Acetate exerts immunomodulatory and anti-inflammatory effects in MS, increasing the levels of brain-derived neurotrophic factor (BDNF), downregulating inflammation-induced demyelination, and promoting the growth of axons and myelin sheaths.

Globally, Glatiramer Acetate has gained widespread application. For instance, in the United States, it is marketed under the brand name Copaxone and has been approved by the Food and Drug Administration (FDA) for the treatment of Multiple Sclerosis. In Western countries with a high prevalence of MS, its efficacy and tolerability have been widely recognized.

In China, on June 28, 2023, "Glatiramer Acetate Injection" officially received approval from the National Medical Products Administration (NMPA) for the treatment of adult patients with relapsing-remitting Multiple Sclerosis (MS), including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS.